Noema Pharma AG
Noema Pharma is a clinical-stage biotech company pioneering therapeutics for CNS-mediated conditions, focusing on developing disease-transforming treatments for orphan and larger patient populations with brain and nervous system disorders. The company is engaged in multiple clinical trials and in-licensed products from Roche, aiming to address high unmet medical needs in CNS disorders.
Industries
Nr. of Employees
small (1-50)
Noema Pharma AG
Patents
Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
US-11883385-B2
View Details
Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
US-11883385-B2
View DetailsProducts
Selective mGluR5 negative allosteric modulator (clinical-stage pain therapy)
A selective small-molecule negative allosteric modulator of mGluR5 developed for management of trigeminal neuralgia; progressed to Phase 2/3 clinical development with supporting preclinical antinociceptive data and prior human safety data.
Selective PDE10A inhibitor (clinical-stage for tics and stuttering)
A potent, selective phosphodiesterase 10A small-molecule inhibitor developed to modulate dopamine D2 receptor signaling for treatment of Tourette Syndrome tics and childhood onset fluency disorder; advanced to Phase 2b with prior human tolerability data and preclinical behavioral validation.
Broad-spectrum monoamine modulator (clinical-stage for vasomotor symptoms)
A broad-spectrum monoaminergic small-molecule modulator developed as a non-hormonal treatment for vasomotor symptoms associated with menopause; supported by preclinical data indicating wake-promoting and metabolic effects and progressed to Phase 2 studies.
Selective mGluR5 negative allosteric modulator (clinical-stage pain therapy)
A selective small-molecule negative allosteric modulator of mGluR5 developed for management of trigeminal neuralgia; progressed to Phase 2/3 clinical development with supporting preclinical antinociceptive data and prior human safety data.
Selective PDE10A inhibitor (clinical-stage for tics and stuttering)
A potent, selective phosphodiesterase 10A small-molecule inhibitor developed to modulate dopamine D2 receptor signaling for treatment of Tourette Syndrome tics and childhood onset fluency disorder; advanced to Phase 2b with prior human tolerability data and preclinical behavioral validation.
Broad-spectrum monoamine modulator (clinical-stage for vasomotor symptoms)
A broad-spectrum monoaminergic small-molecule modulator developed as a non-hormonal treatment for vasomotor symptoms associated with menopause; supported by preclinical data indicating wake-promoting and metabolic effects and progressed to Phase 2 studies.
Services
Public-facing trial information, patient inquiry channels, and clinical trial enrollment support for ongoing studies.
Curated disease-state educational materials and links to patient advocacy organizations for CNS conditions.
Public-facing trial information, patient inquiry channels, and clinical trial enrollment support for ongoing studies.
Curated disease-state educational materials and links to patient advocacy organizations for CNS conditions.
Expertise Areas
- Clinical trial management
- CNS small-molecule drug development
- Preclinical efficacy modeling
- CMC and clinical supply
Key Technologies
- Small-molecule receptor modulators
- GPCR allosteric modulation
- Phosphodiesterase 10A inhibition
- Monoamine reuptake/modulation
News & Updates
Noema Pharma announced its participation in several investor conferences during June and July 2021, including Jefferies Virtual Healthcare Conference, Kempen Life Sciences Crossover Conference, Emerging Biotech Company Showcase, and LifeSci Partners Summer Private Company Symposium.
Noema Pharma announced a webinar featuring Dr. Ali Mostajelean discussing treatments for seizures in TSC, with updates on lead compound NOE-101 entering Phase 2b.
Noema Pharma announced a webinar featuring Dr. Gerald Maguire discussing neurobiology and treatments for stuttering, with a focus on NOE-105.
Noema Pharma announced the first patient dosing in a Phase 2b trial of NOE-101 for pain in trigeminal neuralgia, with top-line data expected in H1 2024.
Noema Pharma announced dosing of the first patient in a Phase 2a study of NOE-115 for vasomotor and other menopause symptoms.
Noema Pharma management will present at BioEquity Europe 2023, providing updates on clinical development and milestones.
Noema Pharma announced its participation in several investor conferences during June and July 2021, including Jefferies Virtual Healthcare Conference, Kempen Life Sciences Crossover Conference, Emerging Biotech Company Showcase, and LifeSci Partners Summer Private Company Symposium.
Noema Pharma announced a webinar featuring Dr. Ali Mostajelean discussing treatments for seizures in TSC, with updates on lead compound NOE-101 entering Phase 2b.
Noema Pharma announced a webinar featuring Dr. Gerald Maguire discussing neurobiology and treatments for stuttering, with a focus on NOE-105.
Noema Pharma announced the first patient dosing in a Phase 2b trial of NOE-101 for pain in trigeminal neuralgia, with top-line data expected in H1 2024.
Noema Pharma announced dosing of the first patient in a Phase 2a study of NOE-115 for vasomotor and other menopause symptoms.
Noema Pharma management will present at BioEquity Europe 2023, providing updates on clinical development and milestones.